Nektar Therapeutics Analyst Ratings
BenzingaMar 6 09:43 ET
Jefferies Adjusts Nektar Therapeutics Price Target to $1 From $0.50, Maintains Hold Rating
MT NewswiresMar 5 12:49 ET
Nektar Therapeutics Analyst Ratings
BenzingaNov 20, 2023 08:28 ET
Nektar Therapeutics Analyst Ratings
BenzingaNov 9, 2023 09:17 ET
Analysts Have Conflicting Sentiments on These Healthcare Companies: Arcus Biosciences (RCUS), Aligos Therapeutics (ALGS) and Nektar Therapeutics (NKTR)
TipRanksNov 8, 2023 01:22 ET
Mizuho Reiterates Neutral on Nektar Therapeutics, Maintains $6 Price Target
BenzingaAug 7, 2023 12:30 ET
Nektar Therapeutics Analyst Ratings
BenzingaAug 7, 2023 12:29 ET
Mizuho Securities Sticks to Their Hold Rating for Nektar Therapeutics (NKTR)
TipRanksAug 7, 2023 10:05 ET
SVB Securities Sticks to Its Hold Rating for Nektar Therapeutics (NKTR)
TipRanksMay 11, 2023 12:47 ET
Jefferies Upgrades Nektar Therapeutics (NKTR) to a Hold
TipRanksMay 10, 2023 04:37 ET
Mizuho Securities Sticks to Its Hold Rating for Nektar Therapeutics (NKTR)
TipRanksMay 9, 2023 23:17 ET
SVB Securities Reaffirms Their Hold Rating on Nektar Therapeutics (NKTR)
TipRanksMay 1, 2023 11:01 ET
Mizuho Securities Reaffirms Their Hold Rating on Nektar Therapeutics (NKTR)
TipRanksApr 27, 2023 17:37 ET
SVB Securities Sticks to Its Hold Rating for Nektar Therapeutics (NKTR)
TipRanksApr 19, 2023 02:01 ET
Goldman Sachs Remains a Sell on Nektar Therapeutics (NKTR)
TipRanksApr 17, 2023 21:06 ET
Analyst Ratings for Nektar Therapeutics
BenzingaMar 6, 2023 15:03 ET
Oppenheimer Adjusts Nektar Therapeutics Price Target to $3 From $5, Maintains Perform Rating
MT NewswiresMar 6, 2023 09:02 ET
Nektar Therapeutics (NKTR) Receives a Hold From Oppenheimer
TipRanksMar 6, 2023 07:26 ET
Oppenheimer Maintains Perform on Nektar Therapeutics, Lowers Price Target to $3
BenzingaMar 6, 2023 07:17 ET
Mizuho Securities Keeps Their Hold Rating on Nektar Therapeutics (NKTR)
TipRanksMar 1, 2023 00:11 ET
No Data
No Data